Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Debt to Equity (2022 - 2026)

Kura Oncology has reported Debt to Equity over the past 5 years, most recently at $0.09 for Q1 2026.

  • Quarterly Debt to Equity rose 244.06% to $0.09 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.09 through Mar 2026, up 244.06% year-over-year, with the annual reading at $0.06 for FY2025, 142.23% up from the prior year.
  • Debt to Equity was $0.09 for Q1 2026 at Kura Oncology, up from $0.06 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.09 in Q1 2026 and troughed at $0.02 in Q1 2024.
  • The 5-year median for Debt to Equity is $0.02 (2023), against an average of $0.03.
  • Year-over-year, Debt to Equity decreased 20.26% in 2024 and then soared 244.06% in 2026.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2022, then rose by 7.8% to $0.02 in 2023, then dropped by 1.99% to $0.02 in 2024, then soared by 142.23% to $0.06 in 2025, then soared by 62.04% to $0.09 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Debt to Equity are $0.09 (Q1 2026), $0.06 (Q4 2025), and $0.04 (Q3 2025).